Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06969755 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Biomarkers to Enhance Early Schizophrenia Treatment

Study acronym: BEEST
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Sep 30, 2025 to Sep 4, 2024v5
  2. Study sites: 4 to 5v4
  3. Study sites: 2 to 4v3
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 1 to 2 · Start date changed from estimate of Jul 30, 2025 to Sep 30, 2025v2 Show 2 more changesShow less
    • Study sites: 1 to 2
    • Start date changed from estimate of Jul 30, 2025 to Sep 30, 2025
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.
Trial Details
NCT Number NCT06969755
Lead Sponsor Northwell Health
Collaborators: National Institute of Mental Health (NIMH)
Conditions Schizophenia Disorder
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov